中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1331 records (took 0.036 seconds)

    SYSTEM AND METHOD FOR AUTOMATED FOCAL SOURCE DETECTION
    91.
    发明申请
    SYSTEM AND METHOD FOR AUTOMATED FOCAL SOURCE DETECTION 审中-公开

    公开(公告)号：WO2023004501A1

    公开(公告)日：2023-02-02

    申请号：PCT/CA2022/051145

    申请日：2022-07-25

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： CHAUHAN, Vijay Singh ,  WANG, Bo ,  LIAO, Shun

    IPC: A61B5/316 ,  A61B5/00 ,  A61B5/318 ,  A61B5/361 ,  G06N3/04 ,  G06N3/08

    Abstract: Various embodiments are described herein for a system, method, and device for automated detection of focal source locations of electrophysiological activity in an organ. The system, method and device may also be used to guide catheter 5 ablation of the organ. An electrogram signal can be obtained from a location in the organ, and it can be determined if the electrogram is periodic. If so, the corresponding unipolar electrogram can be input to a deep learning neural network classification model trained to generate a unipolar electrogram classification result in response to receiving the unipolar electrogram as an input. The location can be identified as a focal 10 source location or a non-focal source location based on the unipolar electrogram classification result.

    MULTIMODAL ANALYSIS OF CIRCULATING TUMOR NUCLEIC ACID MOLECULES
    93.
    发明申请
    MULTIMODAL ANALYSIS OF CIRCULATING TUMOR NUCLEIC ACID MOLECULES 审中-公开

    公开(公告)号：WO2021253138A1

    公开(公告)日：2021-12-23

    申请号：PCT/CA2021/050842

    申请日：2021-06-18

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： BRATMAN, Scott Victor ,  BURGENER, Justin Matthew ,  DINIZ DE CARVALHO, Daniel

    IPC: C12Q1/6809 ,  C12Q1/6886 ,  G16B20/00 ,  G16B30/00 ,  C12Q1/68

    Abstract: In an aspect, there is provided a method of detecting the presence of ctDNA from cancer cells in a subject comprising: (a) providing a sample of cell-free DNA from a subject; (b) subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; (c) optionally adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated, then further optionally denaturing the sample; (d) capturing cell-free methylated DNA using a binder selective for methylated polynucleotides; (e) sequencing the captured cell-free methylated DNA; (f) comparing the sequences of the captured cell-free methylated DNA to control cell-free methylated DNAs sequences from healthy and cancerous individuals; (g) identifying the presence of DNA from cancer cells if there is a statistically significant similarity between one or more sequences of the captured cell-free methylated DNA and cell-free methylated DNAs sequences from cancerous individuals; wherein in at least one of the capturing step, the comparing step or the identifying step, the subject cell-free methylated DNA is limited to a sub-population according to a fragment length metric.

    METHOD OF DETERMINING CANCER CELL STEMNESS
    97.
    发明申请
    METHOD OF DETERMINING CANCER CELL STEMNESS 审中-公开

    公开(公告)号：WO2021223029A1

    公开(公告)日：2021-11-11

    申请号：PCT/CA2021/050633

    申请日：2021-05-06

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： LUPIEN, Mathieu ,  MADANI TONEKABONI, Seyed Ali ,  NADORP, Bettina ,  QAMRA, Aditi

    IPC: C12Q1/6809 ,  C12Q1/6886 ,  G16B20/00 ,  G16B30/00

    Abstract: The present disclosure relates to a method for determining the presence of a cancer stem cell in a cancer sample comprising at least one tumor cell. Chromatin accessibility data is obtained from the cancer sample. A DNA repeat profile is generated based on an enrichment factor of DNA repeats in one or more portions of the chromatin accessibility data. The DNA repeat profile is compared to one or more corresponding reference DNA repeat profiles associated with a cancer stem cell. The reference profile comprises a reference enrichment factor of one or more corresponding portions of the chromatin accessibility data. When the DNA repeat profile for the one or more portions of the chromatin accessibility data matches the one or more first corresponding reference DNA repeat profiles to within a predetermined threshold, a cancer stem cell status is assigned based on the one or more first corresponding reference DNA repeat profiles.

    T CELL RECEPTORS AND METHODS OF USE THEREOF
    99.
    发明申请
    T CELL RECEPTORS AND METHODS OF USE THEREOF 审中-公开

    公开(公告)号：WO2021019471A1

    公开(公告)日：2021-02-04

    申请号：PCT/IB2020/057171

    申请日：2020-07-29

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： HIRANO, Naoto ,  SUGATA, Kenji ,  SASO, Kayoko

    IPC: C12N15/867 ,  A61K35/17 ,  A61P35/00 ,  C07K14/725 ,  C12N15/113 ,  C12N15/12 ,  C12N15/63 ,  C12N5/0783

    Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a MUC5AC epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.

Patent Agency Ranking